Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel
Journal cover image

Sertraline versus imipramine to prevent relapse in chronic depression.

Publication ,  Journal Article
Koran, LM; Gelenberg, AJ; Kornstein, SG; Howland, RH; Friedman, RA; DeBattista, C; Klein, D; Kocsis, JH; Schatzberg, AF; Thase, ME; Rush, AJ ...
Published in: J Affect Disord
June 2001

BACKGROUND: Chronic depressions are common, disabling and under-treated, and long-term treatment is little studied. We report the continuation phase results from a long-term treatment study. METHODS: After 12 weeks of acute phase treatment in a double-blind, randomized, parallel-group, multi-center trial of sertraline or imipramine, patients with chronic depression (> or = 2 years in major depression, or major depression superimposed on dysthymia) continued study drug for 16 weeks. Initially, 635 patients were randomized to sertraline or imipramine in a 2:1 ratio. Nonresponders after 12 weeks entered a 12-week double-blind crossover trial of the alternate medication. Entry into continuation treatment required at least a satisfactory response (partial remission) to initial or crossover treatment. RESULTS: Of 239 acute or crossover responders to sertraline, 60% entered continuation in full remission and 40% with a partial remission. These proportions were identical for imipramine patients (n = 147). For both drug groups, over two-thirds of those entering in full remission retained it. For those entering in partial remission, over 40% achieved full remission. Patients requiring crossover treatment were less likely to maintain or improve their response during continuation treatment. The two drugs did not differ significantly in response distribution, drop out rates or discontinuation due to side effects during continuation treatment. LIMITATIONS: The absence of a placebo group constrains interpretation of our results, but chronic depressions have low placebo response rates. CONCLUSIONS: Most chronic depression patients who remit with 12 weeks of sertraline or imipramine treatment maintain remission during 16 weeks of continuation treatment. Most patients with a satisfactory therapeutic response (partial remission) after 12 weeks of treatment maintain it or further improve. Patients treated with imipramine experienced more side effects, but both drugs were well tolerated.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Affect Disord

DOI

ISSN

0165-0327

Publication Date

June 2001

Volume

65

Issue

1

Start / End Page

27 / 36

Location

Netherlands

Related Subject Headings

  • Sertraline
  • Recurrence
  • Psychiatry
  • Psychiatric Status Rating Scales
  • Middle Aged
  • Male
  • Imipramine
  • Humans
  • Female
  • Dysthymic Disorder
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Koran, L. M., Gelenberg, A. J., Kornstein, S. G., Howland, R. H., Friedman, R. A., DeBattista, C., … Keller, M. B. (2001). Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord, 65(1), 27–36. https://doi.org/10.1016/s0165-0327(00)00272-x
Koran, L. M., A. J. Gelenberg, S. G. Kornstein, R. H. Howland, R. A. Friedman, C. DeBattista, D. Klein, et al. “Sertraline versus imipramine to prevent relapse in chronic depression.J Affect Disord 65, no. 1 (June 2001): 27–36. https://doi.org/10.1016/s0165-0327(00)00272-x.
Koran LM, Gelenberg AJ, Kornstein SG, Howland RH, Friedman RA, DeBattista C, et al. Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord. 2001 Jun;65(1):27–36.
Koran, L. M., et al. “Sertraline versus imipramine to prevent relapse in chronic depression.J Affect Disord, vol. 65, no. 1, June 2001, pp. 27–36. Pubmed, doi:10.1016/s0165-0327(00)00272-x.
Koran LM, Gelenberg AJ, Kornstein SG, Howland RH, Friedman RA, DeBattista C, Klein D, Kocsis JH, Schatzberg AF, Thase ME, Rush AJ, Hirschfeld RM, LaVange LM, Keller MB. Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord. 2001 Jun;65(1):27–36.
Journal cover image

Published In

J Affect Disord

DOI

ISSN

0165-0327

Publication Date

June 2001

Volume

65

Issue

1

Start / End Page

27 / 36

Location

Netherlands

Related Subject Headings

  • Sertraline
  • Recurrence
  • Psychiatry
  • Psychiatric Status Rating Scales
  • Middle Aged
  • Male
  • Imipramine
  • Humans
  • Female
  • Dysthymic Disorder